Clinical Trial Update: Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update shows termination of a tislelizumab study for recurrent mismatch repair-deficient endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Lynch Syndrome
• Mismatch Repair Deficiency

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Floor Backes, MD | Conditions: Lynch Syndrome, Recurrent Endometrial Carcinoma | EARLY_Phase 1 | Status: TERMINATED